{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-094466","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2026-08-12T11:28:40+00:00","discovered_at":"2026-08-12T11:30:00.421381+00:00","generated_at":"2026-08-12T11:30:03.836657+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Milestone Q2 2026 net loss $28.6M; CARDAMYST coverage jumps to ~50% of commercial lives","bullets":["Q2 2026 net loss of $28.6M ($0.21/share) vs $13.0M ($0.20/share) in Q2 2025.","Product revenue $0.6M in Q2; first sales from CARDAMYST launched mid-Feb 2026.","Cash, equivalents, short-term investments $170.6M as of June 30, 2026; runway into H2 2027.","CARDAMYST: >800 prescribers, >1,500 scripts filled; commercial coverage now ~50% via UnitedHealthcare.","Phase 3 ReVeRA-301 AFib-RVR trial sites activated; EMA decision on etripamil for PSVT expected H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-094466","json":"https://secwatch.observer/filing/0001104659-26-094466.json","markdown":"https://secwatch.observer/filing/0001104659-26-094466.md","text":"https://secwatch.observer/filing/0001104659-26-094466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926094466/0001104659-26-094466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926094466/tm2614433d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T11:30:03.836657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}